78 related articles for article (PubMed ID: 10718088)
1. [Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
Steimann RU; Bode JC
Versicherungsmedizin; 2000 Mar; 52(1):24-7. PubMed ID: 10718088
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium.
Delwaide J
Acta Gastroenterol Belg; 2002; 65(4):233-6. PubMed ID: 12619432
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Wong JB; Davis GL; Pauker SG
Am J Med; 2000 Apr; 108(5):366-73. PubMed ID: 10759092
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
Younossi ZM; Singer ME; McHutchison JG; Shermock KM
Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
Kim WR; Poterucha JJ; Gross JB
Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
[No Abstract] [Full Text] [Related]
7. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
Poynard T
Gut; 2003 Oct; 52(10):1532. PubMed ID: 12970155
[No Abstract] [Full Text] [Related]
8. Making it happen: managed care considerations in vanquishing hepatitis C.
McHutchison JG; Bacon BR; Owens GS
Am J Manag Care; 2007 Dec; 13 Suppl 12():S327-36; quiz S337-40. PubMed ID: 18095781
[TBL] [Abstract][Full Text] [Related]
9. What is (cost) effective in patients with chronic hepatitis C virus infection?
Zeuzem S
Eur J Gastroenterol Hepatol; 2001 May; 13(5):473-6. PubMed ID: 11396523
[TBL] [Abstract][Full Text] [Related]
10. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.
Cheng PN; Jen CM; Young KC; Chen CY; Lu SN; Wang CS; Chang TT
Hepatogastroenterology; 2003; 50(50):449-52. PubMed ID: 12749244
[TBL] [Abstract][Full Text] [Related]
11. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Siebert U; Sroczynski G; Wasem J; Greiner W; Ravens-Sieberer U; Aidelsburger P; Kurth BM; Bullinger M; von der Schulenburg JM; Wong JB; Rossol S
Eur J Health Econ; 2005 Jun; 6(2):112-23. PubMed ID: 15902546
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of chronic hepatitis C].
Ferenci P
Wien Med Wochenschr; 2000; 150(23-24):481-5. PubMed ID: 11205179
[TBL] [Abstract][Full Text] [Related]
13. [New therapeutic possibilities in chronic hepatitis C].
Criblez DH
Praxis (Bern 1994); 2000 Mar; 89(11):450-3. PubMed ID: 10758732
[TBL] [Abstract][Full Text] [Related]
14. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea.
Kim JH; Han KH; Lee KS; Park YN; Ahn SH; Chon CY; Moon YM
Yonsei Med J; 2006 Dec; 47(6):793-8. PubMed ID: 17191307
[TBL] [Abstract][Full Text] [Related]
16. [Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
Zeuzem S
Dtsch Med Wochenschr; 1999 May; 124(20):636-42. PubMed ID: 10370387
[No Abstract] [Full Text] [Related]
17. [Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
MMW Fortschr Med; 2003 May; 145(19):55. PubMed ID: 12813986
[No Abstract] [Full Text] [Related]
18. [Minimization of endogenous intoxication syndrome by individual choice of drugs for therapy of chronic hepatitis].
Vasil'eva DK; Goriacheva LG; Kotiv MIa; Alekseeva LA; Romantsov MG; Bessonova TV
Antibiot Khimioter; 2011; 56(3-4):46-50. PubMed ID: 21913409
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
